Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Has the NHS been limiting access to high priced drugs?

Has the NHS been limiting access to high priced drugs? PharmacoEconomics & Outcomes News 759, p4 - 13 Aug 2016 The NHS expanded its early access programme to Has the NHS been limiting access include 22 new delivery networks; however, the new to high priced drugs? centres were given a maximum number they could treat, and were warned that the financial burden of exceeding A joint investigation by the BMJ, and Cambridge and that number would lie with the dispensing provider. Bath Universities has uncovered how NHS England, And although NHS England claims it has been acting faced with a huge bill for Gilead’s pricey breakthrough according to guidance, expert clinicians disagree and are hepatitis-C drug, sofosbuvir, attempted to influence the angered by the tactics. outcome of the NICE process, and after failing to do so, The NHS is also being accused of a broader agenda of rationed access to the drugs in spite of NICE’s trying to hinder NICE’s ability to impose budget- recommendation to make them available breaking recommendations, and have chosen these With launch prices ranging from around $US90 000 drugs and hepatitis C as its battleground because most per patient in the US, £35 000 in the UK and €41 000 in patients with hepatitis http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Has the NHS been limiting access to high priced drugs?

PharmacoEconomics & Outcomes News , Volume 759 (1) – Aug 13, 2016
Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/has-the-nhs-been-limiting-access-to-high-priced-drugs-FeDukqheTI

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
DOI
10.1007/s40274-016-3269-9
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 759, p4 - 13 Aug 2016 The NHS expanded its early access programme to Has the NHS been limiting access include 22 new delivery networks; however, the new to high priced drugs? centres were given a maximum number they could treat, and were warned that the financial burden of exceeding A joint investigation by the BMJ, and Cambridge and that number would lie with the dispensing provider. Bath Universities has uncovered how NHS England, And although NHS England claims it has been acting faced with a huge bill for Gilead’s pricey breakthrough according to guidance, expert clinicians disagree and are hepatitis-C drug, sofosbuvir, attempted to influence the angered by the tactics. outcome of the NICE process, and after failing to do so, The NHS is also being accused of a broader agenda of rationed access to the drugs in spite of NICE’s trying to hinder NICE’s ability to impose budget- recommendation to make them available breaking recommendations, and have chosen these With launch prices ranging from around $US90 000 drugs and hepatitis C as its battleground because most per patient in the US, £35 000 in the UK and €41 000 in patients with hepatitis

Journal

PharmacoEconomics & Outcomes News – Springer Journals

Published: Aug 13, 2016

There are no references for this article.